Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from OptimizeRx ( (OPRX) ).
On August 19, 2025, OptimizeRx Corporation announced leadership changes aimed at accelerating its strategic growth and achieving the Rule of 40 strategy, which balances sustained growth with increased profitability. Brendan Merrell was appointed as the Chief Operating Officer, while Edward Stelmakh transitioned to the role of Chief Financial & Strategic Officer to lead corporate strategy and financial operations. These changes reflect the company’s commitment to aligning talent and structure with its long-term strategic objectives under CEO Steve Silvestro’s management. The leadership advancements, including the promotion of Andy D’Silva to Chief Business Officer, are designed to enhance the company’s focus on profitable growth and shareholder value creation.
The most recent analyst rating on (OPRX) stock is a Hold with a $18.50 price target. To see the full list of analyst forecasts on OptimizeRx stock, see the OPRX Stock Forecast page.
Spark’s Take on OPRX Stock
According to Spark, TipRanks’ AI Analyst, OPRX is a Neutral.
OptimizeRx’s overall stock score is driven by strong technical momentum and a positive earnings call, indicating a solid growth trajectory. However, challenges in profitability and valuation concerns due to negative earnings impact the score. The company’s strategic leadership changes are a positive factor, but the uncertainty in managed service revenue growth requires caution.
To see Spark’s full report on OPRX stock, click here.
More about OptimizeRx
OptimizeRx is a leading healthcare technology company that redefines how life science brands connect with patients and healthcare providers. The company offers innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Headquartered in Waltham, Massachusetts, OptimizeRx partners with leading pharmaceutical and life sciences companies to transform the healthcare landscape.
Average Trading Volume: 317,500
Technical Sentiment Signal: Buy
Current Market Cap: $313M
See more insights into OPRX stock on TipRanks’ Stock Analysis page.